Methotrexate
JYLAMVO, Methotrexate, Otrexup, Rasuvo, Trexall, Xatmep
Folate Analog Metabolic Inhibitor
NADAC/unit
$0.1585
Active Shortage
Tier 1: 180.5%
PA Req: 234.0%
14 Manufacturers
34 ANDAs
a diydrofolate reductase inhibitor indicated for the: • Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ....
vs. brand JYLAMVO: Generic saves up to 98% per unit
Active Shortages
2025-08-29 Discontinuation of the manufacture of the drug, Assertio Specialty Pharmaceuticals, LLC
2025-08-29 Discontinuation of the manufacture of the drug, Assertio Specialty Pharmaceuticals, LLC
2025-08-29 Discontinuation of the manufacture of the drug, Assertio Specialty Pharmaceuticals, LLC
2025-08-29 Discontinuation of the manufacture of the drug, Assertio Specialty Pharmaceuticals, LLC
2025-08-29 Discontinuation of the manufacture of the drug, Assertio Specialty Pharmaceuticals, LLC
Market Intelligence
2023-11-01 Class III Recall: West-Ward Columbus Inc
Generic Manufacturers
ACCORD HEALTHCARE INCALEMBIC PHARMACEUTICALS LTDAZURITY PHARMACEUTICALS INCBARR LABORATORIES INCCAPLIN ONE LABS LTDDAITO PHARMACEUTICAL CO LTDELITE LABORATORIES INCEUGIA PHARMA SPECIALITIES LTDFRESENIUS KABI USA LLCHIKMA PHARMACEUTICALS USA INCHOSPIRA INCMEDEXUS PHARMA INCMYLAN PHARMACEUTICALS INCPHARMACHEMIE BVSAGENT PHARMACEUTICALS INCSHORLA PHARMA LTDSUN PHARMACEUTICAL INDUSTRIES LTDZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.